Battat R, Kopylov U, Bessissow T, Bitton A, Cohen A, Jain A, Martel M, Seidman E, Afif W.
2017.
Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.. Clin Gastroenterol Hepatol. 15(9):1427-1434.e2.
Lukin DJ, Kumar A, Hajifathalian K, Sharaiha RZ, Scherl EJ, Longman RS.
2020.
Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease.. Gastroenterology. 159(4):1541-1544.e2.
Weinstock LB, Bosworth BP, Scherl EJ, Li E, Iroku U, Munsell MA, Mullen GE, Walters AS.
2010.
Crohn's disease is associated with restless legs syndrome.. Inflamm Bowel Dis. 16(2):275-9.
Cohen-Mekelburg S, Gold S, Schneider Y, Dennis M, Oromendia C, Yeo H, Michelassi F, Scherl E, Steinlauf A.
2019.
Delays in Initiating Post-operative Prophylactic Biologic Therapy Are Common Among Crohn's Disease Patients.. Dig Dis Sci. 64(1):196-203.
Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P et al..
2018.
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.. Gastroenterology. 155(3):687-695.e10.
Yang E, Panaccione N, Whitmire N, Dulai PS, Casteele NVande, Singh S, Boland BS, Collins A, Sandborn WJ, Panaccione R et al..
2020.
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.. Aliment Pharmacol Ther. 51(11):1031-1038.
Steinlauf AF, Marion JF, Sacchar D, Sandler AL, Greenstein AJ, Harris MT.
2011.
Ileouterine fistulae: possible predisposing factors to this rare complication of Crohn's disease.. Inflamm Bowel Dis. 17(3):872-3.
Dogan B, Suzuki H, Herlekar D, R Sartor B, Campbell BJ, Roberts CL, Stewart K, Scherl EJ, Araz Y, Bitar PP et al..
2014.
Inflammation-associated adherent-invasive Escherichia coli are enriched in pathways for use of propanediol and iron and M-cell translocation.. Inflamm Bowel Dis. 20(11):1919-32.
Otani T, Yamaguchi K, Scherl E, Du B, Tai H-H, Greifer M, Petrovic L, Daikoku T, Dey SK, Subbaramaiah K et al..
2006.
Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha.. Am J Physiol Gastrointest Liver Physiol. 290(2):G361-8.
Dogan B, Scherl E, Bosworth B, Yantiss R, Altier C, McDonough PL, Jiang Z-D, Dupont HL, Garneau P, Harel J et al..
2013.
Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease.. Inflamm Bowel Dis. 19(1):141-50.
Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M et al..
2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.. Inflamm Bowel Dis. 24(11):2461-2467.
Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P.
2008.
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.. Gastroenterology. 135(4):1130-41.
Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS et al..
2019.
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.. Clin Gastroenterol Hepatol. 17(12):2497-2505.e1.
Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM, Kosinski L, Regueiro MD.
2015.
Ulcerative Colitis Care Pathway.. Gastroenterology. 149(1):238-45.
Qazi T, Verma R, Hamilton MJ, Kaplan ER, Redline S, Burakoff R.
2019.
The Use of Actigraphy Differentiates Sleep Disturbances in Active and Inactive Crohn's Disease.. Inflamm Bowel Dis. 25(6):1044-1053.
Battat R, Kopylov U, Byer J, Sewitch MJ, Rahme E, Nedjar H, Zelikovic E, Dionne S, Bessissow T, Afif W et al..
2017.
Vitamin B12 deficiency in inflammatory bowel disease: a prospective observational pilot study.. Eur J Gastroenterol Hepatol. 29(12):1361-1367.